Thursday, Propanc Biopharma, Inc. (PPCB) announced that its board has approved a share repurchase program, authorizing the company to repurchase up to $5.0 million of its common stock.
The company expects the program to allow the shareholders to continue to increase their ownership in its underlying assets, improve per share economics over time, and signal management's confidence in the long-term value of the business.
Moreover, CEO James Nathanielsz stated that the decision reflects the company's commitment to disciplined, flexible capital allocation.
In the pre-market hours, PPCB is trading at $2.87, up 114.23 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.